Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial

Table 3 Univariate and multivariate analyses for pathological response in patients treated with neoadjuvant endocrine letrozole

Variable¹	Pathological response, n (102)		Odds ratio (95% CI) univariate	p²	Odds ratio (95% CI) multivariate	p²
Variable¹	Yes	No	Odds ratio (95% CI) univariate	p²	Odds ratio (95% CI) multivariate	p²
TILs (%)³ pretreatment			1.20 (0.84–1.72)	0.31
TILs (%)³ posttreatment			0.78 (0.60–1.02)	0.07
TIL change (%)³			0.71 (0.53–0.96)	0.02	0.71 (0.53–0.96)	0.02
KI67 index (%)³ pretreatment			0.99 (0.96–1.01)	0.22
Ki67 index (%)³ posttreatment			0.53 (0.31–0.91)	0.02
Age (years)
60–69	34	28	0.81 (0.36–1.81)	0.61
70–89	24	16	1
Tumour size (mm)				0.03
< 20	31	14	2.46 (1.10–5.57)
≥ 20	27	30	1
Subtype				0.03		0.03
Ductal	46	26	1		1
Other invasive	12	18	0.38 (0.16–0.90)		0.37 (0.15–0.91)
Malignancy grade				0.26
1	22	13	1.07 (0.42–2.66)
2	27	17	1
3	1	4	0.16 (0.02–1.53)
Axillary node status prior to treatment				0.99
Negative	31	24	1
Positive	26	20	1.01 (0.46–2.22)
Unknown	1	0	–
Oestrogen receptor status (%)				0.15
10–99	8	11	0.48 (0.18–1.32)
100	50	33	1
Progesterone receptor status (%)				0.78
0–99	41	32	0.88 (0.36–2.16)
100	16	11	1
Unknown	1	1	–

Data reported as n. ¹Unless otherwise specified, variables are pretreatment values. ²Excluding unknowns. ³Continuous variable, per 10% increase
TILs, tumour-infiltrating lymphocytes

ISSN: 1465-542X